– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically ...